Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FILbiowm study of fondazione italiana linfomi

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAngela FerrariMMMichele MerliECEmanuele Cencini

Discussion

Loading...

Member takes

Overview

Prospective trial evaluates TP53 mutations in bone marrow and cell-free DNA, showing effects on survival in WM patients.

Key Points

  • This study aims to evaluate the frequency and prognostic significance of TP53 mutations in Waldenström Macroglobulinemia.
  • Conducted a multicenter, observational prospective trial (BIOWM)
  • Assessed TP53 mutations in paired bone marrow and peripheral blood samples
  • Utilized targeted next-generation sequencing on a 15-gene panel
  • Analyzed overall survival and progression-free survival using Kaplan-Meier method
  • 31 out of 279 patients had TP53 mutations, with a diagnostic rate of 10% in WM and 14% in IgM-MGUS
  • Cell-free DNA demonstrated a higher detection rate of TP53 mutations compared to bone marrow samples
  • TP53 mutated patients had a trend towards shorter time to treatment and lower overall survival compared to wild-type patients

Cite This Study

Ferrari et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db0fhttps://doi.org/10.1182/blood-2025-5318
View Full Paper
Ask AI
Bookmark
Share